Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Sotatercept in pulmonary arterial hypertension: something different or more of the same?

Nature Cardiovascular Research volume 2, pages 487–488 (2023)Cite this article

Subjects

Sotatercept is the first successful therapy to make it through phase 3 to regulatory submission in pulmonary arterial hypertension that is not proposed to work via vasodilatory mechanisms. The phase 3 STELLAR study of sotatercept treatment challenges established thinking on pulmonary vascular remodeling and offers patients hope for a step change in outcomes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hoeper, M. et al. N. Engl. J. Med. 388, 1478–1490 (2023).

    Article  CAS  PubMed  Google Scholar 

  2. Humbert, M. et al. N. Engl. J. Med. 384, 1204–1215 (2021).

    Article  CAS  PubMed  Google Scholar 

  3. International PPH Consortium. Nat. Genet. 26, 81–84 (2000).

    Article  Google Scholar 

  4. Evans, J. D. W. et al. Lancet Respir. Med. 4, 129–137 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Graf, S. et al. Nat. Commun. 9, 1416 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Dunmore, B. J. et al. Cardiovasc. Res. 117, 2309–2325 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Morrell, N. W. et al. Circulation 104, 790–75 (2001).

    Article  CAS  PubMed  Google Scholar 

  8. Upton, P. D. et al. Am. J. Respir. Cell Mol. Biol. 49, 1135–1145 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ryanto, G. R. T. et al. Nat. Commun. 12, 1720 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yung, L. M. et al. Sci. Transl. Med. 12, eaaz5660 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Upton, P. D. et al. J. Biol. Chem. 284, 15794–15804 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Humbert et al. Eur. Respir. J. 61, 2201347 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Victor Phillip Dahdaleh Heart and Lung Research Institute, Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrookes Hospital, Cambridge, UK

    Mark Toshner

  2. Royal Papworth Hospital, Cambridge Biomedical Campus, Cambridge, UK

    Mark Toshner

Authors
  1. Mark Toshner
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Mark Toshner.

Ethics declarations

Competing interests

M.T. has contributed to scientific advisory boards for MorphogenIX and Janssen Pharmaceuticals, and received support to attend scientific meetings from GSK and Janssen Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toshner, M. Sotatercept in pulmonary arterial hypertension: something different or more of the same?. Nat Cardiovasc Res 2, 487–488 (2023). https://doi.org/10.1038/s44161-023-00283-1

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s44161-023-00283-1

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing